EUCTR2008-001170-32-FR进行中（未招募）不适用
Phase 3 Study of Pemetrexed, Cisplatin, andRadiotherapy Followed by Consolidation Pemetrexedversus Etoposide, Cisplatin, and Radiotherapy Followedby Consolidation Cytotoxic Chemotherapy of Choice inPatients with Unresectable, Locally Advanced, Stage IIINon-Small Cell Lung Cancer Other than PredominantlySquamous Cell Histology - JMIG
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1]Present with histological proven or cytological diagnosis of NSCLC that is defined as nonsquamous (squamous cell histology and/or mixed small cell, non-small cell histology is not permitted)
- •[2]Unresectable Stage IIIA or IIIB NSCLC (without malignant pleural/pericardial effusion).
- •[3]Have an ECOG functional status score of 0 or 1
- •[4]Have tumor lesion measurable according to Response Evaluation Criteria in Solid Tumors
- •[5]Have adequate pulmonary function defined as in the protocol
- •[6]Have normal organ and marrow function as defined in the protocol
- •[7]Weight loss < or = 5% in the preceding 3 months
- •[8]Estimated life expectancy > 12 weeks
- •[9]Age > or = 18 years
- •[10]Signed informed consent from the patient
- •[[11]For women: must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment, and must not be breast-feeding
- •For men: must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period
- •[12]Are compliant with study procedures and should live in a geographic proximity that facilitates adequate follow-up.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[13]Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
- •[14]Have myocardial infarction within the preceding 6 months or symptomatic congestive heart failure, unstable angina pectoris, or uncontrolled cardiac arrhythmia
- •[15]Have received treatment within the last 30 days with any other investigational agents that have not received regulatory approval for any indication at the time of study entry
- •[16]Have disease that is currently amenable to surgery
- •[17]Had prior thoracic or head/neck radiation. However, other prior radiotherapy is allowed. Patients must have recovered from the toxic effects of the treatment prior to study enrollment. Patients may not have received whole pelvis radiation or radiation to more than 25% of their bone marrow (Cristy and Eckermann 1987)
- •[18]Patients whose radiation treatment plans encompass a volume of whole lung receiving > or = 20 Gy in total (V20) of more than 35% of lung volume
- •[19]Concurrent cancer from another primary site requiring treatment of any kind within the past 5 years. Patients cannot have had either breast cancer or melanoma even if more than 5 years previously. Curatively treated nonmelanoma skin cancer or in situ carcinoma of the cervix are allowed
- •[20]Are pregnant, breast feeding, or unwilling to use adequate contraception
- •[21]Patients with immune deficiency (for example, HIV positive)
- •[22]Are unable to interrupt aspirin at a dose < or = 1.3 g/day or other nonsteroidal anti-inflammatory drugs (NSAIDs) for at least 2 days (5 days for long-acting agents [for example, piroxicam]) before, during, and for at least 2 days after administration of pemetrexed
- •[23]Are unable/unwilling to take folic acid, vitamin B12, and dexamethasone
- •[24]Have contraindication or rejection of the use of corticosteroids within 30 days of enrollment, or concurrent yellow fever vaccination (within 30 days of study enrollment)
- •[25]Have evidence of clinical hearing loss.
- •[26] Known hypersensitivity to pemetrexed, cisplatin, etoposide or any of
- •the excipients in these medicinal products.
研究者
相似试验
终止
不适用
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM)KCT0001060Eli Lilly Korea15
已完成
1 期
A Phase I Study of Pemetrexed, Carboplatin, and Radiation Therapy in Locally Advanced Non-Squamous-Cell, Non-Small-Cell Lung Cancerelderly patients with localy advanced non-small-cell lung cancerJPRN-UMIN000014330Osaka Lung Cancer Study Group12
进行中（未招募）
不适用
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125
已完成
不适用
A Phase II Study of Cisplatin, Pemetrexed and Bevacizumab for Advanced Non-Small Cell (Non squamous cell) Lung CancerAdvanced Non-Small Cell (Non squamous cell) Lung CanceJPRN-UMIN000005763Japanese Foundation for Cancer Research, the Cancer Institute Hospital45
进行中（未招募）
1 期
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-NLEli Lilly and Company113